Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus ORTIKOS.
CORTIFOAM vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid